Previously, we discovered that the expression of SOX17, a tumor-suppressive transcriptional regulator with a high mobility group (HMG) box domain that interacts with SRY binding site in DNA, is significantly downregulated due to promoter hypermethylation in ESCC patients with poor prognosis [23]. Here, SOX17 is linked to neoplasm.